We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK, Valeant’s Ezogabine Approval Held Up by Complete Response Letter
GSK, Valeant’s Ezogabine Approval Held Up by Complete Response Letter
December 3, 2010
The FDA has issued a complete response letter for ezogabine, GlaxoSmithKline (GSK) and Valeant Pharmaceuticals’ investigational anti-epileptic drug.